DOCSLIB.ORG

Thrombocytopenia and Neutropenia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Thrombocytopenia and Neutropenia ONLINE EXCLUSIVE Richard W. Temple, MD, Thrombocytopenia and FAAFP; Brittany Burns, DO Camp Lejeune Family Medicine Residency, Naval Medical neutropenia: A structured Center Camp Lejeune, NC (Dr. Temple); Naval Hospital approach to evaluation Pensacola, Fla (Dr. Burns) richard.w.temple2.mil@ mail.mil. These algorithms and tables will help you quickly assess The authors reported no potential conflict of interest the severity of the 2 blood abnormalities and delineate relevant to this article. between life-threatening and benign causes. hrombocytopenia and neutropenia are commonly PRACTICE encountered laboratory abnormalities. The presence RECOMMENDATIONS of either requires that you promptly evaluate for life- ❯ Employ a systematic T threatening causes and identify the appropriate etiology. This approach to the diagnosis and article identifies key questions to ask. It also includes algo- treatment of thrombocytope- rithms and tables that will facilitate your evaluation of patients nia and neutropenia. C with isolated thrombocytopenia or isolated neutropenia and ❯ Do not transfuse platelets in speed the way toward appropriate treatment. patients with platelet counts >10,000/mcL who are stable and are not undergoing an Thrombocytopenia: invasive procedure. C A look at the numbers ❯ Monitor patients on Thrombocytopenia is defined as a platelet count <150,000/mcL.1 heparin therapy for >4 days The blood abnormality is either suspected based on the pa- for heparin-induced tient’s signs or symptoms, such as ecchymoses, petechiae, pur- thrombocytopenia. C pura, epistaxis, gingival bleeding, or melena, or it is incidentally ❯ Monitor (for life) patients discovered during review of a complete blood count (CBC). with a history of gastric The development of clinical symptoms is closely related bypass for the development of to the severity of the thrombocytopenia, with platelet counts nutritional neutropenias. C <30,000/mcL more likely to result in clinical symptoms with Strength of recommendation (SOR) minor trauma and counts <5,000/mcL potentially resulting in A Good-quality patient-oriented spontaneous bleeding. While most patients will have asymp- evidence tomatic, incidentally-found thrombocytopenia, and likely a B Inconsistent or limited-quality patient-oriented evidence benign etiology, those with the signs/symptoms just described, C Consensus, usual practice, evidence of infection, or thrombosis are more likely to have a opinion, disease-oriented serious etiology and require an expedited work-up. Although evidence, case series pregnancy may be associated with thrombocytopenia, this re- view confines itself to the causes of thrombocytopenia in non- pregnant adults. Rule out pseudothrombocytopenia When isolated thrombocytopenia is discovered incidentally in an asymptomatic person, the first step is to perform a repeat MDEDGE.COM/JFPONLINE VOL 67, NO 7 | JULY 2018 | THE JOURNAL OF FAMILY PRACTICE E1 CBC with a peripheral smear to confirm the TABLE 1 presence of thrombocytopenia, rule out labo- Medications that can induce ratory error, and assess for platelet clumping. 3 If thrombocytopenia is confirmed and plate- thrombocytopenia let clumping is present, it may be due to the • Abciximab • Gentamicin calcium chelator in the ethylenediaminetet- • Captopril • Hydrochlorothiazide/ raacetic anticoagulant contained within the triamterene • Cilastatin/imipenem laboratory transport tube; this cause of pseu- • Meropenem dothrombocytopenia occurs in up to 0.29% • Clopidogrel of the population.1 Obtaining a platelet count • Phenytoin from a citrated or heparinized tube avoids • Dactinomycin/ • Piperacillin actinomycin this phenomenon. • Quinine • Digoxin • Spironolactone Is the patient’s thrombocytopenia • Dipyridamole drug induced? • Tirofiban Once true thrombocytopenia is confirmed, the • Drospirenone/ • TNF-alpha/INF- ethinylestradiol next step is to review the patient’s prescribed gamma medications, as well as any illicit drugs used, • Eptifibatide • Trimethoprim/ sulfamethoxazole for potential causes of drug-induced throm- • Famotidine Immune- bocytopenia. DITP can be either immune- • Vancomycin • Fluconazole mediated mediated or nonimmune-mediated. • Vaccines: Hepatitis B drug-induced ❚ Immune-mediated DITP typically oc- • Furosemide and influenza thrombocyto- curs within 1 to 2 weeks of medication ex- penia typically posure and begins to improve within 1 to occurs within 2 days of stopping the offending drug.2 (See Is there thrombosis? 1 to 2 weeks TABLE 13 for a list of medications that can in- In addition to exploring a connection be- of medication duce thrombocytopenia.) It should be noted tween thrombocytopenia and the drugs a exposure and that most patients who take the medications patient is taking, it’s also important to look begins to listed in TABLE 1 do not experience thrombo- for evidence of thrombosis. The causes of improve within cytopenia; nonetheless, it is a potential risk thrombocytopenia that paradoxically result 1 to 2 days associated with their use. in thrombosis are: disseminated intravascu- of stopping the ❚ Heparin-induced thrombocytopenia lar coagulation, hemolytic uremic syndrome, offending drug. (HIT) is a unique form of immune-mediated thrombotic thrombocytopenic purpura, DITP in that it is caused by antibody complex- catastrophic antiphospholipid antibody syn- es, resulting in platelet activation, clumping, drome, and the previously mentioned HIT. and thrombotic events.4 HIT occurs in <1% of TABLE 24,6-9 outlines the clinical settings, labo- patients in intensive care units, but can occur ratory findings, and treatments of thrombo- in any patient on long-term heparin therapy. cytopenia associated with thrombosis. It manifests as a >50% drop in platelet count within 5 to 14 days of the introduction of hep- Is an infectious cause to blame? arin; however, in those previously exposed to If the patient is ill, consider infectious causes heparin, it can occur within 24 hours.4,5 of thrombocytopenia. Thrombocytopenia as- ❚ Non-immune-mediated DITP, result- sociated with infection may result from an ing from myelosuppression, chemotherapeu- immune-mediated response to an illness it- tic agents, or valproic acid, is less common.1,2 self, to treatment of an illness, to splenic se- ❚ Acute and chronic alcohol use. Al- questration, or to bone marrow suppression. though alcohol is not a drug per se, it can also TABLE 31,9-11 lists common infections that may result in thrombocytopenia. The mechanism cause thrombocytopenia. is the direct suppression of bone marrow, Of note, infection with Helicobacter py- although alcohol also causes B12 and folate lori can cause asymptomatic thrombocytope- 12 deficiency, further contributing to the devel- nia via an immune-mediated mechanism. 1 opment of the blood abnormality. Eradication of H pylori results in a variable E2 THE JOURNAL OF FAMILY PRACTICE | JULY 2018 | VOL 67, NO 7 THROMBOCYTOPENIA/NEUTROPENIA TABLE 2 Thrombocytopenia associated with thrombosis4,6-9 Diagnosis Clinical setting Laboratory findings Treatment Disseminated intravascular Sepsis fibrinogen Treat underlying cause coagulation Malignancy d-dimer Cryoprecipitate Trauma Prolonged PT, aPTT Fresh frozen plasma Hemolytic uremic syndrome Kidney injury Creatinine Supportive Shiga-toxin-producing Anemia Dialysis Escherichia coli infection Schistocytes Thrombotic Neurologic deficit LDH Plasmapheresis thrombocytopenic purpura Anemia Schistocytes ADAMTS13 gene Heparin-induced Current or past heparin + serotonin release assay Anticoagulation (non-heparin) thrombocytopenia exposure Antibodies to heparin-platelet factor 4 complex Antiphospholipid antibody Vascular thrombosis Anticardiolipin antibody Anticoagulation syndrome Pregnancy complications Lupus anticoagulant Anti-beta2 glycoprotein aPTT, activated partial thromboplastin time; ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; LDH, lactate dehydrogenase; PT, prothrombin time. elevation in platelets, on average 30,000/mcL TABLE 3 in 50% of patients with the infection.13 Common infectious causes of 1,9-11 Is there pancytopenia? thrombocytopenia A review of the peripheral smear, with atten- Viral Cytomegalovirus, Epstein-Barr tion to abnormalities in other cell lines, may virus, hepatitis B and C, human assist in arriving at a diagnosis. If the periph- immunodeficiency virus, parvovirus B19 eral smear reveals pancytopenia, then, in addition to many of the etiologies described Bacterial Ehrlichiosis, Helicobacter pylori, Rocky Mountain spotted fever earlier, one should also consider vitamin B12 or folate deficiency, copper deficiency, drug- and viral-induced aplastic anemia, paroxys- (HIT, H pylori infection, etc). Consider ITP if, mal nocturnal hemoglobinuria, leukemias, after a thorough work-up, a cause of isolated myelodysplastic disorders, and systemic thrombocytopenia is not identified.16 Treat- lupus erythematosis.14 Pancytopenia is also ment for ITP is outlined in TABLE 4.16 FIGURE 1 seen with hypersplenism, which is often as- is an algorithm for the complete evaluation of sociated with cirrhosis.15 If the etiology isn’t thrombocytopenia in adults. readily apparent, a bone marrow biopsy may be required. Treatment: Platelet transfusions Is immune thrombocytopenia to blame? In general, patients who are not actively Immune thrombocytopenia (ITP) is an auto- bleeding are considered stable and do not re- immune disorder resulting in the destruction quire platelet transfusions to minimize their of normal platelets and may
Load more

Recommended publications
  • Protein S Deficiency Presenting with Hemorrhage in a Term Neonate
    : Curre re nt a R C e Ayari et al., Health Care Current Reviews 2018, 6:1 h v t i l e a w DOI: 10.4172/2375-4273.1000219 e s H Health Care: Current Reviews ISSN: 2375-4273 Review Article Open Access Protein S Deficiency Presenting with Hemorrhage in a Term Neonate Fairouz Ayari*, Takoua Bensmail, Essid Latifa, Wiem Barbaria and Samia Kacem Neonatology Intensive Care Unit of the Maternity and Neonatology Center, Tunis, Tunisia Abstract Unexplained bleeding symptoms in otherwise healthy full-term usually present a diagnostic challenge for treating physicians requiring prompt and accurate laboratory investigations to ensure appropriate treatment and possibly avoid long-term morbidity. We report a case of a term neonate with severe protein S deficiency manifested by systemic hemorrhage and multiple organ failure at 9 days of age. We review how protein S influences the coagulation and the fibrinolytic pathways, discussing therapeutic approaches of neonates with purpura fulminans. Keywords: Protein S deficiency; Blood sample; Thrombophilic dis- resuscitation with 20 ml/kg bodyweight (BW) saline solution and, after order blood sampling, intravenous administration of 10 mg vitamin K, 20 ml/kg BW fresh frozen plasma, 20 ml/kg BW packed red blood cells Introduction (5 transfusion cycles), 20 mg/kg BW Phenobarbital and vasoactive Protein S (PS) is an antithrombotic plasma protein that acts mainly drugs. Cerebral ultrasound revealed intraventricular haemorrhage, as a cofactor of activated protein C (APC) anticoagulant activity in the abdominal ultrasound showed splenic hemorrhage and cardiac degradation of factor Va and activated factor VIII [1]. PS circulates in ultrasound showed a floating intracardiac thrombus.
    [Show full text]
  • Infection Control for Neutropenic Cancer Patients : the Libraryuse of Prophylactic Antibiotics Lecture Author Jean A
    Infection control for neutropenic cancer patients : the Libraryuse of prophylactic antibiotics Lecture author Jean A. Klastersky Onlineby Institut Jules Bordet,© Université Libre de Bruxelles (ULB) Brussels, Belgium ESCMID Complications and mortality associated with febrile neutropenia Library No Bacteremia Bacteremia Total ComplicationsLectureDeaths Total Complications Deaths author Solid tumors 784 60 (8 %) 25 135 30 (22 %) 17 Onlineby (3 %) (13 % ) © Hematological cancer 859 111 (13 %) 32 364 76 (21 %) 32 (4 %) (9 %) ESCMID J. Klastersky et al., 2007 2 Complications associated with febrile neutropenia Library Hypotension : systolic blood pressure less than 90 mmHg or need for pressor support to maintain blood pressure Respiratory failure : arterial oxygen pressure less than 60mmHg while breathing room air or needLecture for mechanical ventilation Disseminated intravascular coagulation Confusion or altered mental state author Congestive cardiac failure seen on chest X-ray and requiring treatment Onlineby Bleeding severe enough to require© transfusion Arrhythmia or ECG changes requiring treatment Renal failure requiring investigation and/or treatment with IV fluids, dialysis, or any other intervention ESCMID J. Klastersky et al., 2000 3 Cost of febrile neutropenia Library Initial hospitalization Initial hospitalization plus all downstreamLecture neutropenia care author 2.010 $ Onlineby 14.407 $ © ESCMID D. Weyckler et al., 2008 4 Use of oral antibiotics in protected units environment : clinical effectiveness and role in the emergence
    [Show full text]
  • Neutropenia Fact Sheet
    Neutropenia in Barth Syndrome i ii (Chronic, Cyclic or Intermittent) What problems can Neutropenia cause? Neutrophils are the main white blood cell for fighting or preventing bacterial or fungal infections. They may be referred to as polymorphonuclear cells (polys or PMNs), white cells with segmented nuclei (segs), or neutrophils in the complete blood cell count (CBC) report. Immature neutrophils are referred to as bands. When someone is neutropenic (an abnormally low level of neutrophils in the blood), the risk of infection increases. The absolute neutrophil count (ANC) is a measure of the total number of neutrophils present in the blood. When the ANC is less than 1,000, the risk of infection increases. Most infections occur in the ears, skin or throat and to a lesser extent, the chest. These infections can be very serious and may require antibiotics to clear infections. When someone with Barth syndrome is neutropenic his defenses are weakened, he is likely to become seriously ill more quickly than someone with a normal neutrophil count. Tips: • No rectal temperatures as any break in the skin can lead to an infection. • If the individual has a temperature > 100.4° F (38° C) or has infectious symptoms, the primary physician or hematologist should be notified. The individual may need to be seen. • If the individual has a temperature of 100.4° F (38° C) – 100.5° F (38.05° C)> 8 hours or a temperature > 101.5° F (38.61° C), an immediate examination by the physician is warranted. Some or all of the following studies may be ordered: CBC with differential and ANC Urinalysis Blood, urine, and other appropriate cultures C-Reactive Protein Echocardiogram if warranted • The physician may suggest antibiotics (and G-CSF if the ANC is low) for common infections such as otitis media, stomatitis.
    [Show full text]
  • Understanding the CBC
    Understanding the CBC What is Hematology? Hematology is the science of blood and blood-forming tissues. Blood is made up of plasma and blood cells. Blood formation (hematopoesis) is a continuous process that occurs in the bone marrow. Within the bone marrow there is a pluripotent stem cell, the Mother Cell, the originator of all types of blood cells. The stem cell produces blood cells that exit the bone marrow and circulate in the blood system. Red cells circulate about four months, platelets last an average of ten days, and white cells range from only hours to a week or so. Stem cells that are found outside the bone marrow are called “peripheral stem cells” and are collected and frozen for stem cell transplants. What is a CBC? The CBC- the complete blood count, or the counts- is a lab test that will be ordered frequently on your child. This test determines the number, type, percentage, concentration and quality of the various types of blood cells that make up the blood. This test can be completed on blood that is collected by a finger stick, a lab draw from a central vein access and/or a straight draw from a peripheral vein, (usually from an arm, hand or foot). The CBC is commonly performed on an automated analyzer. However when abnormalities are noted in the blood, parts of the test can be completed manually. That is when the blood sample is viewed under the microscope. Some institutions commonly perform an extensively complete CBC and others may perform just specific aspects of the CBC.
    [Show full text]
  • Vancomycin-Resistant Enterococci Colonization in Patients with Hematological Malignancies: Screening and Its Cost-Effectiveness
    Vancomycin-resistant enterococci colonization in patients with hematological malignancies: screening and its cost-effectiveness Gedik Habip1, Şimşek Funda1, Kantürk Arzu1, Yıldırmak Taner1, Arıca Deniz2, Aydın Demet2, Yokuş Osman2, Demirel Naciye2 1. Department of Infectious Diseases and Clinical Microbiology, Ministry of Health Okmeydanı Training and Research Hospital, Istanbul 2. Department of Hematology, Ministry of Health Okmeydanı Training and Research Hospital, Istanbul Abstract: Background and objective: We evaluated the rates of vancomycin-resistant enterococci (VRE) colonization and VRE- related bacteremia in patients with hematological malignancies in terms of routine screening culture and its cost-effective- ness. Materials and Methods: All patients of the hematology department who were older than 14 years of age and who devel- oped at least one febrile neutropenia episode during chemotherapy for hematological cancers between November 2010 and November 2012 were evaluated retrospectively. Results: We retrospectively analyzed 282 febrile episodes in 126 neutropenic patients during a two-year study period. The study included 65 cases in the first study-year and 78 cases in the second study-year. The numbers of colonization days and colonized patient were748 days of colonization in 29 patients (44%) in the first study-year and 547 colonization days in 21 patients (26%) in the second study-year, respectively. Routine screening culture for VRE cost $4516,4 (427 cultures) in the first study-year, $5082,7 (504 cultures) in the second study-year depending on the number of patients and their length of stay. Conclusion: In line with our study results, routine screening of hematological patients for VRE colonization is not cost- effective. Routine surveillance culture for VRE should be considered with respect to the conditions of health care setting.
    [Show full text]
  • Azathioprine and Mercaptopurine Therapy
    Patient & Family Guide 2021 Azathioprine and Mercaptopurine Therapy www.nshealth.ca Azathioprine and Mercaptopurine Therapy Your health care provider feels that treatment with azathioprine (a-za-THY-o-preen) (Imuran®) or mercaptopurine (mur-CAP-toe-pure-een) (6-MP) may help you manage an over-active immune response. This pamphlet will help you decide if this medication is right for you. It describes what azathioprine is, how it works, and possible side effects. What are azathioprine (AZA) and mercaptopurine (6-MP)? • The cells in your immune system fight infection and inflammation (swelling). • If your immune system is over-active, it can can cause inflammation and damage to body tissues and organs. • Diseases that cause an over-active immune response are: › Rheumatoid arthritis › Inflammatory bowel disease (IBD), such as Crohn’s disease and ulcerative colitis › Certain forms of liver disease • AZA is an immunosuppressive medication. It suppresses (weakens) the immune response, which lowers inflammation. 1 • 6-MP is very similar to AZA. It works much the same way, but your body breaks it down in a different way. This makes it less likely to cause nausea (feeling sick to your stomach) and vomiting (throwing up). 6-MP costs more than azathioprine. If you have nausea or vomiting when taking AZA, talk to your health care provider. How well does AZA work? Will it work for me? • AZA, when used alone, helps to control diseases that cause an over-active immune response in many people, including IBD. • Take this medication as told by your doctor. This increases the chance that it will work well.
    [Show full text]
  • Outcomes of Patients with Thrombocytopenia Evaluated at Hematology Subspecialty Clinics
    Henry Ford Health System Henry Ford Health System Scholarly Commons Hematology Oncology Articles Hematology-Oncology 2-11-2021 Outcomes of patients with thrombocytopenia evaluated at hematology subspecialty clinics Zaid H. Abdel Rahman Kevin C. Miller H Jabbour Yaser Alkhatib Vijayalakshmi Donthireddy Follow this and additional works at: https://scholarlycommons.henryford.com/ hematologyoncology_articles Hematol Oncol Stem Cell Ther xxx (xxxx) xxx Available at www.sciencedirect.com ScienceDirect journal homepage: www.elsevier.com/locate/hemonc Outcomes of patients with thrombocytopenia evaluated at hematology subspecialty clinics Zaid H. Abdel Rahman a,*, Kevin C. Miller b, Hiba Jabbour c, Yaser Alkhatib c, Vijaya Donthireddy c a Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL, USA b Department of Medicine, Massachusetts General Hospital, Boston, MA, USA c Division of Hematology and Medical Oncology, Henry Ford Hospital, Detroit, MI, USA Received 6 October 2020; received in revised form 9 December 2020; accepted 15 January 2021 KEYWORDS Abstract Hematology; Background: Thrombocytopenia is a frequently encountered laboratory abnormality and a Malignancy; common reason for hematology referrals. Workup for thrombocytopenia is not standardized Platelets; and frequently does not follow an evidence-based algorithm. We conducted a systematic anal- Referrals; Thrombocytopenia ysis to evaluate the laboratory testing and outcomes of patients evaluated for thrombocytope- nia at hematology clinics in a tertiary referral center between 2013 and 2016. Patient and methods: We performed a comprehensive chart review for patients evaluated for thrombocytopenia during the study period. Patients were followed for 1 year from the initial hematology evaluation and assessed for the development of a hematologic malignancy, rheumatologic, or infectious diseases among other clinical outcomes.
    [Show full text]
  • Severe Fever with Thrombocytopenia Syndrome: a Newly Discovered Emerging Infectious Disease
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector REVIEW Severe fever with thrombocytopenia syndrome: a newly discovered emerging infectious disease D. X. Li Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China Abstract Severe fever with thrombocytopenia syndrome (SFTS) is a newly discovered emerging infectious disease that has recently become epidemic in Asia. The causative agent of SFTS is a novel phlebovirus in the family Bunyaviridae, designated SFTS virus (SFTSV). SFTS clinically presents with high fever, thrombocytopenia, leukocytopenia, gastrointestinal disorders, and multi-organ dysfunction, with a high viral load and a high case- fatality rate. In human infection, SFTSV targets microphages, replicates in the spleen of infected mice, and causes thrombocytopenia and a cytokine storm. The tick disseminates virus to humans and animals, forming a special transmission model in nature. Person-to-person transmission though direct contact with patient blood has been frequently reported. Measurements of viral RNA and antibodies have been established for diagnosis, but vaccines and specific therapeutics are not available so far. Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Keywords: Clinical, epidemiology, SFTS virus, SFTS, virology Article published online: 11 March 2015 Virology D.X. Li, Key Laboratory for Medical Virology, NCHFP, RRC, National Institute for Viral Disease Control and Prevention, China CDC, Bei- jing 102206, China E-mail: [email protected] The causative agent of SFTS is SFTSV, which is a tick-borne virus in the family Bunyaviridae, genus Phlebovirus.
    [Show full text]
  • Bone Marrow Suppression (Myelosuppression) and Leukopenia/Neutropenia
    Effects on the Hematopoietic System: Bone Marrow Suppression (Myelosuppression) and Leukopenia/Neutropenia Effects on the Hematopoietic System: Bone Marrow Suppression (Myelosuppression) and Leukopenia/Neutropenia Author: Ayda G. Nambayan, DSN, RN, St. Jude Children’s Research Hospital Erin Gafford, Pediatric Oncology Education Student, St. Jude Children’s Research Hospital; Nursing Student, School of Nursing, Union University Content Reviewed by: Monika Metzger, MD, St. Jude Children’s Research Hospital Cure4Kids Release Date: 6 June 2006 Leukopenia is a decrease in the absolute number of white blood cells, whereas neutropenia is the condition in which the absolute neutrophil count (ANC) is either < 500/mm3 or <1000/mm3 with a predictable decline to <500/mm3 in 24 to 48 hours. Leukopenia and neutropenia can be caused by cancer or by myelosuppression secondary to therapy (chemotherapy and radiation therapy). Infection is the most common complication associated with neutropenia and the major cause of morbidity and mortality in neutropenic patients with cancer. Important determinants of the risk of infection include the number of circulating neutrophils and the duration of the neutropenia. The lower the number of circulating neutrophils is and the longer the neutropenia lasts, the higher the incidence and the more severe the infections are. Children and adolescents with severe neutropenia (ANC< 500/mm3) are at risk of life- threatening bacterial, fungal and viral infections. If the patient has febrile neutropenia (A – 1), surveillance cultures and more blood tests should be conducted to determine whether infection is present and, if it is, where it is located. Assessment Patient assessment must include a careful history and physical examination.
    [Show full text]
  • Severe Myelotoxicity Associated with Thiopurine S-Methyltransferase*3A
    Case Report DOI: 10.4274/tjh.2013.0082 Severe Myelotoxicity Associated with Thiopurine S-Methyltransferase*3A/*3C Polymorphisms in a Patient with Pediatric Leukemia and the Effect of Steroid Therapy Pediatrik Bir Lösemi Olgusunda Tiyopurin S-Metiltransferaz *3A/*3C Polimorfizmi ile İlişkili Ağır Miyelotoksisite-Steroid Tedavisinin Etkisi Burcu Fatma Belen1, Türkiz Gürsel1, Nalan Akyürek2, Meryem Albayrak3, Zühre Kaya1, Ülker Koçak1 1Gazi University Faculty of Medicine, Department of Pediatric Hematology, Ankara, Turkey 2Gazi University Faculty of Medicine, Department of Pathology, Ankara, Turkey 3Kırıkkale University Faculty of Medicine, Department of Pediatric Hematology, Ankara, Turkey Abstract: Myelosuppression is a serious complication during treatment of acute lymphoblastic leukemia and the duration of myelosuppression is affected by underlying bone marrow failure syndromes and drug pharmacogenetics caused by genetic polymorphisms. Mutations in the thiopurine S-methyltransferase (TPMT) gene causing excessive myelosuppression during 6-mercaptopurine (MP) therapy may cause excessive bone marrow toxicity. We report the case of a 15-year-old girl with T-ALL who developed severe pancytopenia during consolidation and maintenance therapy despite reduction of the dose of MP to 5% of the standard dose. Prednisolone therapy produced a remarkable but transient bone marrow recovery. Analysis of common TPMT polymorphisms revealed TPMT *3A/*3C. Key Words: Myelosuppression, Thiopurine S-methyl transferase, Acute leukemia Özet: Miyelosupresyon,
    [Show full text]
  • Neonatal Leukopenia and Thrombocytopenia
    Neonatal Leukopenia and Thrombocytopenia Vandy Black, M.D., M.Sc., FAAP March 3, 2016 April 14, 2011 Objecves • Summarize the differenHal diagnosis of leukopenia and/or thrombocytopenia in a neonate • Describe the iniHal steps in the evaluaon of a neonate with leukopenia and/or thrombocytopenia • Review treatment opHons for leukopenia and/ or thrombocytopenia in the NICU Clinical Case 1 • One day old male infant admiUed to the NICU for hypoglycemia and a sepsis rule out • Born at 38 weeks EGA by SVD • Birth weight 4 lbs 13 oz • Exam shows a small cephalohematoma; no dysmorphic features • PLT count 42K with an otherwise normal CBC Definions • Normal WBC count 9-30K at birth – Mean 18K • What is the ANC and ALC – <1000/mm3 is abnormal – 6-8% of infants in the NICU • Normal platelet count: 150-450,000/mm3 – Not age dependent – 22-35% of infants in the NICU have plts<150K Neutropenia Absolute neutrophil count <1500/mm3 Category ANC* InfecHon risk • Mild 1000-1500 None • Moderate 500-1000 Minimal • Severe <500 Moderate to Severe (Highest if <200) • Recurrent bacterial or fungal infecHons are the hallmark of symptomac neutropenia! • *ANC = WBC X % (PMNs + Bands) / 100 DefiniHon of Neutropenia Black and Maheshwari, Neoreviews 2009 How to Approach Cytopenias • Normal vs. abnormal (consider severity) • Malignant vs. non-malignant • Congenital vs. acquired • Is the paent symptomac • Transient, recurrent, cyclic, or persistent How to Approach Cytopenias • Adequate vs. decreased marrow reserve • Decreased producHon vs. increased destrucHon/sequestraon Decreased neutrophil/platelet producon • Primary – Malignancy/leukemia/marrow infiltraon – AplasHc anemia – Genec disorders • Secondary – InfecHous – Drug-induced – NutriHonal • B12, folate, copper Increased destrucHon/sequestraon • Immune-mediated • Drug-induced • Consumpon à Hypersplenism vs.
    [Show full text]
  • Enterococcal Bacteremia in Febrile Neutropenic Children and Adolescents with Underlying Malignancies, and Clinical Impact of Vancomycin Resistance
    Infection (2019) 47:417–424 https://doi.org/10.1007/s15010-018-1260-z ORIGINAL PAPER Enterococcal bacteremia in febrile neutropenic children and adolescents with underlying malignancies, and clinical impact of vancomycin resistance Kil‑Seong Bae1,2 · Ju Ae Shin1 · Seong koo Kim1,3 · Seung Beom Han1,2 · Jae Wook Lee1,3 · Dong‑Gun Lee2,3,4 · Nack‑Gyun Chung1,3 · Bin Cho1,3 · Dae Chul Jeong1,2 · Jin Han Kang1,2 Received: 28 August 2018 / Accepted: 15 December 2018 / Published online: 19 December 2018 © Springer-Verlag GmbH Germany, part of Springer Nature 2018 Abstract Purpose Enterococci are a common cause of bacteremia in immunocompromised patients. Although the increase of van- comycin-resistant enterococci (VRE) makes appropriate antibiotic therapy difficult, clinical characteristics of enterococcal bacteremia and the impact of VRE infection on outcomes have rarely been reported in immunocompromised children. Methods We enrolled children and adolescents (< 19 years of age) with underlying malignancies who were diagnosed with enterococcal bacteremia during febrile neutropenia between 2010 and 2017. Medical records of the enrolled children were retrospectively reviewed to evaluate the clinical characteristics of enterococcal bacteremia and impact of VRE infection on outcomes. Results Thirty-six episodes of enterococcal bacteremia were identified in 30 patients. VRE infection was identified in 11 epi- sodes (30.6%); the 7- and 30-day mortalities were 27.8% and 44.4%, respectively. Acute lymphoblastic leukemia (50.0%) and acute myeloid leukemia (30.6%) were the most common underlying disorders. Three (8.3%) of the patients were in complete remission, and palliative and reinduction chemotherapies were administered in 47.2% and 36.1% of episodes, respectively.
    [Show full text]